Tyra Net Income Per Share from 2010 to 2026
| TYRA Stock | | | USD 36.54 1.80 5.18% |
Tyra Biosciences' shows a shrinking structural trend supported by multi-year data. Financial forecasts anticipate softening toward -2.11. Regression distribution of quarterly values from 2010 to 2026 reveals a coefficient of variation of
-125.21 . with significance of
0.000017 .
View All Fundamentals Net Loss | First Reported 2010-12-31 | Previous Quarter -2.01 | Current Value -2.11 | Quarterly Volatility 0.76462243 |
Macro event markers
Credit Downgrade | Yuan Drop | Covid | Interest Hikes |
provides competitor comparison context for Tyra Biosciences. The view supports competitor context.
Our
How to Buy Tyra Stock guide explains the steps to invest in Tyra Biosciences stock.
Analyzing Tyra Biosciences's Net Income Per Share over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income Per Share has evolved provides context for assessing Tyra Biosciences's current valuation and future prospects.
Latest Tyra Biosciences' Net Income Per Share Growth Pattern
Below is the plot of the Net Income Per Share of Tyra Biosciences over the last few years. It is Tyra Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tyra Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income Per Share | 10 Years Trend | | |
Tyra Net Income Per Share Regression Statistics
| Arithmetic Mean | -0.61 |
| Coefficient Of Variation | -125.21 |
| Mean Deviation | 0.65 |
| Median | -0.1 |
| Standard Deviation | 0.76 |
| Sample Variance | 0.58 |
| Range | 2.0146 |
| R-Value | -0.85 |
| Mean Square Error | 0.17 |
| R-Squared | 0.72 |
| Significance | 0.000017 |
| Slope | -0.13 |
| Total Sum of Squares | 9.35 |
Tyra Net Income Per Share History
| 2026 | -2.11 | |
| 2025 | -2.01 | |
| 2024 | -1.51 | |
| 2023 | -1.62 | |
| 2022 | -1.32 | |
| 2021 | -0.63 | |
| 2020 | -0.22 | |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California. Tyra Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. As a mid-cap equity, Tyra Biosciences is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 7.01. Tyra Biosciences has market cap of 1.82 B, ROE of -39.83%.
Methodology
Unless otherwise specified, financial data for Tyra Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Tyra (USA Stocks:TYRA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Tyra Biosciences is covered by 11 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
More Resources for Tyra Stock Analysis
Reviewing Tyra Biosciences commonly begins with
financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends.
Selected reports below provide context for Tyra Stock: Tyra Biosciences Correlation provides competitor comparison context for Tyra Biosciences. The view supports competitor context.
Our
How to Buy Tyra Stock guide explains the steps to invest in Tyra Biosciences stock.
Analysis related to Tyra Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Earnings Share -2.01 | Return On Assets | Return On Equity |
Understanding Tyra Biosciences includes distinguishing between market value and book value, where book value reflects Tyra accounting equity. Tyra Biosciences' market capitalization is 1.82 B. With a P/B ratio of 7.01, the market values Tyra Biosciences well above its book equity. Enterprise value stands at 1.57 B. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for Tyra Biosciences differs from its quoted price, since each reflects a different lens. For Tyra Biosciences, key inputs include a P/B ratio of 7.01, and ROE of -39.83%. Trading price represents the transaction level agreed by market participants.